Shares slid as Rocket Lab moved to nearly double its cash reserves by selling up to $1 billion in new stock, raising a pointed question: can the company's Pentagon-fueled growth justify the dilution hit?
• A Billion-Dollar Shelf Offering Replaces One Already Spent. Rocket Lab entered an at-the-market equity distribution agreement allowing it to sell up to $1 billion in common stock over time, replacing an exhausted $750 million program. Unlike a single large stock sale, this structure lets the company drip shares into the market gradually — less disruptive in theory, but a persistent overhang in practice. Shares fell 9.1% on the announcement day alone. At today's $68.97, RKLB sits 28.6% below its January 52-week high of $96.30. The company ended 2025 with roughly 573 million diluted shares outstanding, already up 14.2% year-over-year. At current prices, selling the full $1 billion would add approximately 14.5 million shares — modest percentage dilution, but it signals the company still can't fund its ambitions from operations alone.
• The Cash Pile Was Already Large — So Why Raise More? The filing comes despite a solid cash reserve: Rocket Lab reported $828.66 million in total cash and equivalents as of December 31.
The company said it intends to use proceeds for future growth, including potential acquisitions, plus general corporate purposes and working capital. Translation: Neutron, its bigger rocket still in development, and its expanding satellite manufacturing business are expensive. With a trailing net loss of -$198 million and -$271 million in levered free cash flow , the company is burning cash faster than it earns it.
• A $1.85 Billion Backlog Gives Bulls Something to Hold Onto. Rocket Lab ended 2025 with a $1.85 billion contracted backlog up 73% year-over-year, including an $816 million Space Development Agency contract for 18 satellites and a $190 million Department of War contract for 20 hypersonic test flights.
Non-GAAP gross margin expanded 10 points to 44.3% in Q4 2025, while Q1 2026 guidance projects $185M–$200M in revenue, representing 57% year-over-year growth. The business is clearly scaling.
• Macro Headwinds Make Growth Stocks an Especially Tough Sell. Since the Iran conflict started, risky assets have been hammered as oil prices spiked and odds of rate cuts have been slashed.
At a price-to-sales ratio above 61x , RKLB remains priced for perfection — and dilution announcements in a risk-off market are exactly the kind of catalyst that punishes premium valuations. Clear Street initiated coverage with a "buy" rating and an $88 price target, roughly in line with the $88.38 Wall Street consensus — implying analysts still see upside, if shareholders can stomach the near-term pain.